Company is providing two million QuickVue®
At-Home OTC COVID-19 Tests for “Say Yes! COVID Test” community
health initiative in Pitt County, NC, and Chattanooga/Hamilton
County, TN
Study seeks to determine if frequent at-home
COVID-19 testing helps residents reduce community transmission of
SARS-CoV-2
Quidel Corporation (NASDAQ: QDEL) (“Quidel”), a leading
provider of rapid diagnostic testing solutions, cellular-based
virology assays and molecular diagnostic systems, announced today
that it is partnering with the Centers for Disease Control and
Prevention (CDC) and the National Institutes of Health (NIH) on an
innovative community health initiative called “Say Yes! COVID Test”
in Pitt County, North Carolina, and coming soon to
Chattanooga/Hamilton County, Tennessee. Quidel is providing two
million QuickVue® At-Home OTC COVID-19 Tests to be distributed to
approximately 160,000 residents free of charge across the two
communities. The study is designed to determine if access to
at-home rapid antigen tests three times a week for one month can
significantly reduce virus spread in vulnerable communities.
Quidel’s QuickVue® At-Home OTC COVID-19 Test is a visually read
assay for the qualitative detection of the nucleocapsid protein
antigen from SARS-CoV-2 and requires no instrument to perform the
test. The easy-to-use QuickVue® At-Home OTC COVID-19 Test will
allow the program’s participants to easily perform the test
themselves and get results in 10 minutes. The QuickVue® At-Home OTC
COVID-19 Test shows excellent performance, with positive results
agreeing with PCR 83.5% of the time, and negative results agreeing
99.2% of the time, delivering peace of mind to people running the
test and facilitating reporting of results to the public health
initiative’s sponsors via a customized app developed for the “Say
Yes! COVID Test” initiative.
Quidel’s QuickVue® At-Home OTC COVID-19 Test is being supplied
through the NIH Rapid Acceleration of Diagnostics (RADxSM)
initiative. Selection of the two communities was based on local
infection rates, public availability of accurate COVID-19 tracking
data, existing community relationships through the NIH Rapid
Acceleration of Diagnostics Underserved Populations (RADx-UP) and
local infrastructure to support the project.
“This testing initiative is the first of this scale to attempt
to make free, rapid, self-administered tests available
community-wide in order to determine their effectiveness in our
nation’s comprehensive response to the COVID-19 pandemic,” said NIH
Director Francis S. Collins, M.D., Ph.D. “We hope to gain
foundational data that can guide how communities can use
self-administered tests to mitigate viral transmission during this
and future pandemics.”
Routine testing by rapid antigen tests has shown to be effective
in diagnosing COVID-19.1 Further, a self-administered rapid test
produces results at home in minutes, while laboratory processing
takes longer and increases cost.
“Scientific evidence is emerging that serial COVID-19 testing
with rapid antigen tests can catch infected people early and
empower them to take steps to protect themselves, their families
and their entire community,” said Douglas Bryant, president and CEO
of Quidel Corporation. “As citizens and as a company, Quidel has
worked to support the greatest need and the greatest good as we
democratize access to frequent and affordable coronavirus testing.
This partnership with CDC and NIH to show the power of serial
testing to contain virus spread in underserved communities is
emblematic of that commitment.”
In addition to CDC, NIH and Quidel, the “Say Yes! COVID Test”
initiative is a collaboration with the state and local public
health departments in North Carolina and Tennessee, NIH, research
institutions including Duke University, the University of North
Carolina, North Carolina Central University, test manufacturer
Quidel, healthcare technology company CareEvolution, community
engagement partners from RADx-UP, and Community-Campus Partnerships
for Health.
For more information on the QuickVue® At-Home OTC COVID-19 Test
visit www.quickvueathome.com.
This project is supported by the NIH Rapid Acceleration of
Diagnostics - Advanced Technology Platforms (RADx-ATP) program and
has been funded in whole or in part with Federal funds from the
Office of the Director, National Institutes of Health, Department
of Health and Human Services, under Contract No.
75N92020C00013.
-
https://www.medrxiv.org/content/10.1101/2021.03.19.21253964v2
About Quidel Corporation
Quidel Corporation (Nasdaq: QDEL) is a leading manufacturer of
diagnostic solutions at the point of care, delivering a continuum
of rapid testing technologies that further improve the quality of
health care throughout the globe. An innovator for over 40 years in
the medical device industry, Quidel pioneered the first FDA-cleared
point-of-care test for influenza in 1999 and was the first to
market a rapid SARS-CoV-2 antigen test in the U.S. Under trusted
brand names Sofia®, Solana®, Lyra®, Triage® and QuickVue®, Quidel’s
comprehensive product portfolio includes tests for a wide range of
infectious diseases, cardiac and autoimmune biomarkers, as well as
a host of products to detect COVID-19. With products made in
America, Quidel’s mission is to provide patients with immediate and
frequent access to highly accurate, affordable testing for the good
of our families, our communities and the world. For more
information about Quidel, visit quidel.com.
View our story told by our people at www.quidel.com/ourstory
Forward-Looking Statements
This press release contains forward-looking statements within
the meaning of the federal securities laws that involve material
risks, assumptions and uncertainties. Many possible events or
factors could affect our future results and performance, such that
our actual results and performance may differ materially from those
that may be described or implied in the forward-looking statements.
As such, no forward-looking statement can be guaranteed.
Differences in actual results and performance may arise as a result
of a number of factors including, without limitation: the impact
and duration of the COVID-19 global pandemic; competition from
other providers of diagnostic products; our ability to accurately
forecast demand for our products and products in development,
including in new market segments; our ability to develop new
technologies, products and markets and to commercialize new
products; our reliance on sales of our COVID-19 and influenza
diagnostic tests; our reliance on a limited number of key
distributors; quantity of our product in our distributors’
inventory or distribution channels; changes in the buying patterns
of our distributors; the financial soundness of our customers and
suppliers; lower than anticipated market penetration of our
products; third-party reimbursement policies and potential cost
constraints; our ability to meet demand for our products;
interruptions, delays or shortages in the supply of raw materials,
components and other products and services; failures in our
information technology and storage systems; our exposure to data
corruption, cyber-based attacks, security breaches and privacy
violations; international risks, including but not limited to,
economic, political and regulatory risks; continuing worldwide
political and social uncertainty; our development, acquisition and
protection of proprietary technology rights; intellectual property
risks, including but not limited to, infringement litigation; the
loss of Emergency Use Authorizations for our COVID-19 products and
failures or delays in receipt of reviews or regulatory approvals,
clearances or authorizations for new products or related to
currently-marketed products by the U.S. Food and Drug
Administration (the “FDA”) or other regulatory authorities or loss
of any previously received regulatory approvals, clearances or
authorizations or other adverse actions by regulatory authorities;
our contracts with government entities involve future funding,
compliance and possible sanctions risks; product defects; changes
in government policies and regulations and compliance risks related
thereto; our ability to manage our growth strategy and successfully
identify, acquire and integrate potential acquisition targets or
technologies and our ability to obtain financing; our acquisition
of Alere’s Triage® business presents certain risks to our business
and operations; the level of our deferred payment obligations; our
exposure to claims and litigation that could result in significant
expenses and could ultimately result in an unfavorable outcome for
us, including the ongoing litigation between us and Beckman
Coulter, Inc.; we may need to raise additional funds to finance our
future capital or operating needs; our debt, deferred and
contingent payment obligations; competition for and loss of
management and key personnel; business risks not covered by
insurance; changes in tax rates and exposure to additional tax
liabilities or assessments; and provisions in our charter documents
and Delaware law that might delay or impede stockholder actions
with respect to business combinations or similar transactions.
Forward-looking statements typically are identified by the use of
terms such as “may,” “will,” “should,” “might,” “expect,”
“anticipate,” “estimate,” “plan,” “intend,” “goal,” “project,”
“strategy,” “future,” and similar words, although some
forward-looking statements are expressed differently. The risks
described in reports and registration statements that we file with
the Securities and Exchange Commission from time to time, should be
carefully considered, including those discussed in Item 1A, “Risk
Factors” and elsewhere in our Annual Report on Form 10 K for the
year ended December 31, 2020 and in our subsequent Quarterly
Reports on Form 10 Q. You are cautioned not to place undue reliance
on these forward-looking statements, which reflect management’s
analysis only as of the date of this press release. Except as
required by law, we undertake no obligation to publicly release any
revision or update of these forward-looking statements, whether as
a result of new information, future events or otherwise.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210331006070/en/
Quidel Contact: Quidel Corporation Randy Steward Chief Financial
Officer (858) 552-7931 Media and Investors Contact: Quidel
Corporation Ruben Argueta (858) 646-8023 rargueta@quidel.com
QuidelOrtho (NASDAQ:QDEL)
Historical Stock Chart
From Jun 2024 to Jul 2024
QuidelOrtho (NASDAQ:QDEL)
Historical Stock Chart
From Jul 2023 to Jul 2024